Loading...
XNASGLMD
Market cap5mUSD
Dec 24, Last price  
3.04USD
1D
0.33%
1Q
-57.12%
Jan 2017
-99.52%
IPO
-99.88%
Name

Galmed Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XNAS:GLMD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-28.20%
Rev. gr., 5y
63.12%
Revenues
0k
0000467,0001,085,0002,038,00000000
Net income
-7m
L-62.78%
-3,149,000-17,485,000-9,103,000-10,622,000-16,953,000-12,299,000-9,856,000-18,541,000-27,610,000-31,948,000-18,571,000-6,912,000
CFO
-6m
L-66.83%
-3,079,000-2,524,000-9,241,000-8,474,000-12,129,000-12,067,000-9,023,000-14,937,000-26,287,000-32,892,000-18,501,000-6,137,000
Earnings
Apr 02, 2025

Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
URL
http://www.galmedpharma.com
IPO date
Mar 13, 2014
Employees
4
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
7,523
17,686
32,923
Unusual Expense (Income)
NOPBT
(7,523)
(17,686)
(32,923)
NOPBT Margin
Operating Taxes
705
(519)
Tax Rate
NOPAT
(7,523)
(18,391)
(32,404)
Net income
(6,912)
-62.78%
(18,571)
-41.87%
(31,948)
15.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,185
70
17,368
BB yield
-490.82%
-0.05%
-3.23%
Debt
Debt current
41
171
Long-term debt
41
88
458
Deferred revenue
Other long-term liabilities
Net debt
(15,825)
(15,026)
(34,357)
Cash flow
Cash from operating activities
(6,137)
(18,501)
(32,892)
CAPEX
(4)
(11)
Cash from investing activities
800
17,563
11,462
Cash from financing activities
6,185
70
17,368
FCF
(7,311)
(18,177)
(32,385)
Balance
Cash
12,642
13,785
34,815
Long term investments
3,265
1,500
Excess cash
15,907
15,285
34,815
Stockholders' equity
(193,197)
(186,715)
(168,275)
Invested Capital
207,117
200,353
199,001
ROIC
ROCE
EV
Common stock shares outstanding
231
1,676
1,640
Price
5.46
-93.93%
90.00
-72.53%
327.60
-41.48%
Market cap
1,260
-99.16%
150,856
-71.92%
537,212
-32.36%
EV
(14,565)
135,830
502,855
EBITDA
(7,492)
(17,651)
(32,881)
EV/EBITDA
1.94
Interest
11
215
43
Interest/NOPBT